AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback